Dr. Geraldine, PhD

Hey friends, I’m Geraldine Ezeka #BlackInCancerRollCall. I’m a 5th year PhD candidate @UMmedschool identifying different molecular targets of sulforaphane, a nature derived anti-cancer agent, in mesothelioma.

5 Tips for Turning Your PhD Internship into a Full-Time Offer! medium.com/vanguardstem-c…

hey STEMverse: during your PhD (or research experience), did you find that 1 of the limitations to your progress was 1) inadequate reagents (ex antibodies that sucked) 2) inadequate equipment (ex equipment didn’t do as suggested) or 3) improper protocol 4) or a mix of the above?

Another twist... FDA permits use of Sarepta Therapeutics’ $SRPT Duchenne therapy in younger patients after short-lived halt statnews.com/2025/07/28/sar…

The $SRPT rollercoaster is not over. FDA recommended removal of voluntary hold on Elevidys for ambulatory patients and the $SRPT stock shot up ~50% after close, consistent with that trend, it’s up 40% at open.

$ABVX going from $10 to $69 after reporting positive Phase 3 data that no one believed in is insane. We were obvs bullish and anticipated a >100% increase upon positive data

Yesterday GHRS stocks were up 85%. Excited to continue watching the story develop as we anticipate an update on the clinical hold, an end of Phase 2 meeting with the FDA, and their Ph3 design.

Current standard of care JnJ’s SPRAVATO displayed a 4 point reduction in MADRS score while GH001 achieved a placebo adjusted 15 point reduction in MADRS

Yesterday was a great day in neuropsychiatric drug development with GH Research reporting positive results from the Ph 2 trial evaluating their inhalation formulation of DMT for treatment resistant depression

Let’s chat about Reviva Pharma Reviva Pharma is a clinical stage pharmaceutical company developing a serotonin/dopamine modulators in a host of indications with the lead being schizophrenia

Sometimes good data isn’t all a company needs to be successful.

@AmdayMed Thanks doc! Appreciate ya!

@__GhD_ Thank you so much, I appreciate that! It’s really nice to see you doing big things in the STEM space, I’m wishing you the best as well!

Let’s go Amday!!!!

Cassava stocks plummet 85%…again, not a surprise considering the inconclusive Phase 2 results which begs the question, why did the FDA let them run a Phase 3?

A disheartening day for Alzheimer’s disease drug developers with disappointing results coming from both Cassava Sciences and Alector/Abbvie Phase 3 and Phase 2 clinical trials, respectively. Albeit the Cassava results were expected considering little impact seen in Phase 2

@AmdayMed It has been! Wishing you the best of luck in your journey to and through residency! I know you’ll be amazing!

@__GhD_ Geraldine! Long time, thank you doc!!

I’m here to talk about science, biotech, biotech stocks (OUTSIDE OF MY COVERAGE) and banter.

@Beth_Kindig What’s your investment thesis for investing in $NVDA?

Morgan Stanley estimates that Nvidia’s $NVDA Blackwell chip revenue could be between $5B to $6B in the fourth quarter.

@EthanInvests Oh I completely agree, interested in $MRNA for that exact reason, especially with positive recent data in solid tumors. COVID helped fund the cancer initiatives for sure

@__GhD_ May be, but many vaccines are not mandatory anyhow and mRNA technology is interesting for me in the field of cancer. Especially $BNTX betting heavily on it. They had this focus even before COVID. COVID helped them to get well funded.

Hi! @EthanInvests Thoughts on investing in psychedelic therapeutic companies?

@EthanInvests Also looking at $EDIT myself, haven’t invested yet 🤭

@__GhD_ Not so far. My investments in Biotech in general have not been a big success so far... Difficult to predict market. Ginkgo is different from the rest. I am invested in $MRNA $BNTX $EDIT and $IFRX

@EthanInvests Also curious about how vaccine companies (like $MRNA) will take a hit after Trump appoints different folks in office that may not support vaccines

@EthanInvests Hard to predict since market is heavily dependent on success of clinical trials. A bit easier to follow the data for small/midcap therapeutics companies but more difficult to predict for more service based companies like Ginkgo.